Skip to main content
. 2017 Mar;51:104–112. doi: 10.1016/j.neurobiolaging.2016.11.017

Fig. 1.

Fig. 1

The cerebrospinal fluid/plasma albumin ratio (Qalb) in different diagnostic groups and APOE genotypes in cohort 1. (A) The Qalb in cognitively healthy controls and patients with stable mild cognitive impairment (sMCI), MCI that progressed to Alzheimer's disease (MCI-AD), AD, dementia with Lewy bodies or Parkinson's disease with dementia (DLB/PDD), vascular dementia (VaD), and frontotemporal dementia (FTD). (B) The Qalb in different diagnostic groups stratified according to APOE genotype (APOE ε4 carriers vs. noncarriers). Data are presented as mean ±95% confidence interval; p-values are from univariate general linear models controlling for age and gender: p < 0.05 and ∗∗p < 0.01, compared with controls.